New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
08:34 EDTCYTRCytRx says had positive meeting with FDA to discuss potential Phase 3 trial
The company announced that it has held a positive meeting with the FDA to discuss a potential Phase 3 pivotal trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. “We are planning to submit a special protocol assessment for the Phase 3 trial in patients with advanced soft tissue sarcomas,” said President and CEO Steven A. Kriegsman. “An agreement with the FDA with regards to an SPA would provide a clear regulatory pathway through the approval process. The initiation of a Phase 3 program for our lead drug candidate aldoxorubicin would represent a significant milestone in CytRx’s efforts to bring value to our stockholders and for those patients suffering from soft tissue sarcoma.”
News For CYTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
06:09 EDTCYTRCytRx announces positive data from Phase 1b/2 study of Aldoxorubicin
Subscribe for More Information
October 17, 2014
09:17 EDTCYTROn The Fly: Pre-market Movers
Subscribe for More Information
06:15 EDTCYTRCytRx aldoxorubicin trial not yet reached enough survival events to report OS
CytRx announced that data regarding the company's Phase 2b global clinical trial of aldoxorubicin for the treatment of first-line soft tissue sarcoma, or STS, will be presented in a moderated paper presentation at the 2014 Connective Tissue Oncology Society Annual Meeting which is being held October 15-18, 2014, in Berlin, Germany. Due to the longer than expected survival of patients in the clinical trial, there have not been a sufficient number of survival events to enable the company to report data on overall survival, or OS, a secondary endpoint of the study.
October 13, 2014
06:03 EDTCYTRCytRx commenced operations at new discovery laboratory
Subscribe for More Information
October 9, 2014
06:15 EDTCYTRCytRx initiates Phase 1b combination trial of Aldoxorubicin, Gemcitabine
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use